Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Pharmacokinetics of clobazam oral soluble film.

Heller AH, Wargacki S, Jung C, Buan CV, Wyatt DJ, Schobel AM.

Epilepsia. 2018 Nov;59(11):2153-2161. doi: 10.1111/epi.14581. Epub 2018 Oct 24.

PMID:
30357823
2.

Frequent detection of parental consanguinity in children with developmental disorders by a combined CGH and SNP microarray.

Fan YS, Ouyang X, Peng J, Sacharow S, Tekin M, Barbouth D, Bodamer O, Yusupov R, Navarrete C, Heller AH, Pena SDj.

Mol Cytogenet. 2013 Sep 20;6(1):38. doi: 10.1186/1755-8166-6-38.

3.

Alu insertion polymorphisms in Native Americans and related Asian populations.

Battilana J, Fagundes NJ, Heller AH, Goldani A, Freitas LB, Tarazona-Santos E, Munkhbat B, Munkhtuvshin N, Krylov M, Benevolenskaia L, Arnett FC, Batzer MA, Deininger PL, Salzano FM, Bonatto SL.

Ann Hum Biol. 2006 Mar-Apr;33(2):142-60.

PMID:
16684689
4.

Intra- and intercontinental molecular variability of an Alu insertion in the 3' untranslated region of the LDLR gene.

Heller AH, Salzano FM, Barrantes R, Krylov M, Benevolenskaya L, Arnett FC, Munkhbat B, Munkhtuvshin N, Tsuji K, Hutz MH, Carnese FR, Goicoechea AS, Freitas LB, Bonatto SL.

Hum Biol. 2004 Aug;76(4):591-604.

PMID:
15754974
5.

The influence of age and gender on the pharmacokinetics of moxifloxacin.

Sullivan JT, Lettieri JT, Liu P, Heller AH.

Clin Pharmacokinet. 2001;40 Suppl 1:11-8.

PMID:
11352437
6.

Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.

Isaacsohn J, Zinny M, Mazzu A, Lettieri J, Heller AH.

Eur J Clin Pharmacol. 2001 Mar;56(12):897-903.

PMID:
11317478
7.

Update to the PhRMA perspective on population and individual bioequivalence.

Barrett JS, Batra V, Chow A, Cook J, Gould AL, Heller AH, Lo MW, Patterson SD, Smith BP, Stritar JA, Vega JM, Zariffa N.

J Clin Pharmacol. 2000 Jun;40(6):571-2. No abstract available.

PMID:
10868306
8.

PhRMA perspective on population and individual bioequivalence.

Barrett JS, Batra V, Chow A, Cook J, Gould AL, Heller AH, Lo MW, Patterson SD, Smith BP, Stritar JA, Vega JM, Zariffa N.

J Clin Pharmacol. 2000 Jun;40(6):561-70. Review.

PMID:
10868305
9.

Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.

Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH.

Antimicrob Agents Chemother. 1999 Nov;43(11):2793-7.

10.

Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.

Stein E, Isaacsohn J, Stoltz R, Mazzu A, Liu MC, Lane C, Heller AH.

Am J Cardiol. 1999 May 15;83(10):1433-6.

PMID:
10335757
12.

Preclinical and clinical pharmacology of cerivastatin.

Bischoff H, Heller AH.

Am J Cardiol. 1998 Aug 27;82(4B):18J-25J. Review.

PMID:
9737642
13.
14.

Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.

Shah A, Lettieri J, Blum R, Millikin S, Sica D, Heller AH.

J Antimicrob Chemother. 1996 Jul;38(1):103-16.

PMID:
8858462
15.

Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.

Israel DS, Stotka J, Rock W, Sintek CD, Kamada AK, Klein C, Swaim WR, Pluhar RE, Toscano JP, Lettieri JT, Heller AH, Polk RE.

Clin Infect Dis. 1996 Feb;22(2):251-6.

PMID:
8838180
16.

Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects.

Shah A, Lettieri J, Nix D, Wilton J, Heller AH.

Antimicrob Agents Chemother. 1995 Apr;39(4):1003-6.

17.

Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis.

Shah A, Krol G, Sundaresan P, Lettieri J, Falk R, Lasseter K, Heller AH.

Am J Ther. 1995 Jan;2(1):15-19.

PMID:
11850642
18.

Safety and tolerance of intravenous nimodipine.

Sramek JJ, Heller AH, Sundaresan PR, Lettieri J, Sawin S, Cutler NR.

Ann Pharmacother. 1994 Oct;28(10):1143-8.

PMID:
7841566
19.

Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily.

Shah A, Lettieri J, Kaiser L, Echols R, Heller AH.

J Antimicrob Chemother. 1994 Apr;33(4):795-801.

PMID:
8056698
20.

Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin.

Echols R, Weinstein MP, O'Keeffe B, Shah A, Heller AH.

J Antimicrob Chemother. 1994 Jan;33(1):111-8.

PMID:
8157551
21.

Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.

Israel D, Gillum JG, Turik M, Harvey K, Ford J, Dalton H, Towle M, Echols R, Heller AH, Polk R.

Antimicrob Agents Chemother. 1993 Oct;37(10):2193-9.

22.

Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.

Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH.

Antimicrob Agents Chemother. 1992 May;36(5):993-6.

23.

Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood.

Finberg RW, Newburger JW, Mikati MA, Heller AH, Burns JC.

J Pediatr. 1992 Mar;120(3):376-80.

PMID:
1538283
24.

Idioventricular rhythm: hypervagotonia associated with placebo.

Cutler NR, Heller AH, Kurtz NM, Sramek JJ Jr, Lynch TE, Zolnouni PP, Gandhi DK, Sawin S.

DICP. 1991 May;25(5):471-2.

PMID:
2068830
25.

Arrhythmia due to hypervagotonia in a fit pharmacology volunteer.

Cutler NR, Heller AH, Kurtz NM, Sramek JJ Jr, Lynch TE, Pourdihimi Zolnouni P, Gandhi DK.

Lancet. 1990 Sep 1;336(8714):567. No abstract available.

PMID:
1975060
26.

Ipsapirone: evidence for efficacy in depression.

Heller AH, Beneke M, Kuemmel B, Spencer D, Kurtz NM.

Psychopharmacol Bull. 1990;26(2):219-22.

PMID:
1978372
27.

Efficacy of phenytoin, procainamide, and tocainide in murine genetic myotonia.

Aichele R, Paik H, Heller AH.

Exp Neurol. 1985 Feb;87(2):377-81.

PMID:
3917928
28.

Lobar intracerebral hematomas.

Harrington H, Heller AH.

Neurology. 1984 Jan;34(1):133-4. No abstract available.

PMID:
6537846
29.

Anticonvulsant sensitivity of absence seizures in the tottering mutant mouse.

Heller AH, Dichter MA, Sidman RL.

Epilepsia. 1983 Feb;24(1):25-34.

PMID:
6401628
30.

Glycine receptor alteration in the mutant mouse spastic.

White WF, Heller AH.

Nature. 1982 Aug 12;298(5875):655-7. No abstract available.

PMID:
6285205
31.

Myotonia, a new inherited muscle disease in mice.

Heller AH, Eicher EM, Hallett M, Sidman RL.

J Neurosci. 1982 Jul;2(7):924-33.

32.

The impact of an educational program on gentamicin use in a teaching hospital.

Johnson MW, Mitch WE, Heller AH, Spector R.

Am J Med. 1982 Jul;73(1):9-14.

PMID:
7091176
33.

Electrophysiological studies with the spastic mutant mouse.

Heller AH, Hallett M.

Brain Res. 1982 Feb 25;234(2):299-308.

PMID:
7059832
34.
35.

Education vs restriction in rational use of antibiotics.

Spector R, Heller AH.

Hosp Formul. 1978 Apr;13(4):273-5. No abstract available.

PMID:
10306917

Supplemental Content

Loading ...
Support Center